Imperial Chemical Industries PLCexpects earnings from its pharmaceuticals operations to grow  to about 35 pct of world profits within the next five yearscompared with a current 30 pct, chairman elect Denys Hendersontold financial analysts.    "Over the next five years we expect to launch one major newproduct each year," Henderson said.    He also said research and development spending in thisbusiness segment will be increased to 14 pct of total salesincome in 1987 from 13 pct, or 130 mln sterling, in 1986.    ICI, the world's fifth largest chemicals firm in terms ofsales, recently reported 1986 profits of about 888 mln dlrs on15 billion dlrs in sales, compared with income of 817 mln dlrson 15.87 billion dlrs in sales a year earlier.    Sales in the United States totaled about three billiondlrs, ICI executives said.    In addition, Henderson said overall corporate growth willcome from ICI's research and development activities, but thecompany intends to continue to grow through an acquisitionprogram.    ICI spent just under one billion dlrs for acquisitionsduring 1986, the largest of which was the 580 mln dlr purchaseof Cleveland, Ohio-based Glidden Inc, a paints, resins andcoatings company, from &lt;Hanson Trust PLC>.    ICI financial director Alan Clements said the company'sborrowing limits are at a level of about 6.3 billion sterling,1.5 billion of which have already been used.    While the company has no current plans for a majoracquisition, "we are ready to move quickly in the acquisitionfield if the need arises," Clements said. Reuter&#3;